At this year's ACHEMA (Frankfurt, 18 to 22 June), the Berlin-based biotech company OrganoBalance GmbH will present its most recent findings on the potential uses of yeast strains in the biotechnological production of fine chemicals and new ingredients for pharmaceuticals, cosmetics, foods or feedstuffs (metabolic engineering of yeasts).
In his talk, The yeast Saccharomyces cerevisiae as platform organism for the biotechnological production of miscellaneous industrial relevant compounds, Dr Andreas Raab, Director Research at OrganoBalance, will provide a comprehensive outline of the said topic (22 June at 12.30 pm in hall 9.1, room Esprit).
Prof. Christine Lang, the company's founder and CEO, will focus on newly developed products in the field of specific probiotic microorganisms during her talk, Lactobacilli and yeasts - new ways with old friends, as part of the session Food biotechnology - Whole cells (21 June at 11.30 am in hall 4C, room Consens). When pursuing new developments in this field, OrganoBalance can draw on the potential of its own collection of more than 8,000 natural yeasts and lactic acid bacteria.
“Our unparalleled expertise in the metabolic engineering of yeasts has enabled us to greatly increase the efficiency and sustainability of a number of our partners' manufacturing processes, as well as develop completely new methods”, Dr Raab explains.
Prof. Lang adds: “We're looking forward to ACHEMA, along with the opportunity to share our latest research results and visions with a wider audience. New manufacturing technologies and processes will continue to change the face of biotechnology with lightning speed. OrganoBalance has long been actively involved in such developments, and will remain so in the future.”
Visitors interested in further information on current projects are welcome to visit OrganoBalance at the communal booth of the VBU Association of German Biotechnology Companies, stand C62 in hall 9.2. Appointments can be made online.
OrganoBalance GmbH (organobalance.com) is a company specialising in microbiological strain development. The company targets the use of Saccharomyces cerevisiae yeast strains for synthesising materials which can be applied in the processes of industrial and pharmaceutical biotechnology. OrganoBalance also taps the potential of beneficial microorganisms, known as specific probiotic cultures, in order to balance out microflora in a natural way and restore the microbial equilibrium.
By drawing on its own collection of microorganisms suitable for use in foodstuffs, as well as its own OASSYS® screening systems, OrganoBalance develops new biological products in the areas of pharmaceutics, preventive healthcare, nutrition and cosmetics. OrganoBalance was founded in 2001 and is based in Berlin, Germany.
T: +49 (0) 30 46307-200 / F: +49 (0) 30 46307-210